Modern announces that it has sent a vaccine for a specific variant, mRNA-1273.351, to the National Institutes of Health (NIH) for clinical research
Modern sent its vaccine doses to the specific variant, mRNA-1273.351, against the SARS-CoV-2 variant that was first identified in South Africa, to the National Institutes of Health (NIH) for clinical research.
The company presented two strategies for dealing with the worrying variants.
The company is considering strengthening the vaccine doses in order to increase the ability of the neutralizing antibody effect of the vaccine. Modern examines three approaches to boosting immunity:
- mRNA-1273.351: a specific vaccine dose for the variant that was first identified in South Africa;
- mRNA-1273.211: A complex vaccine dose that combines mRNA-1273, the modernized vaccine against modern strains and mRNA-1273.351 in one vaccine;
- Third dose of mRNA-1273 vaccine: Modern vaccine against COVID-19, at a dose of 50 μg, as a booster.
- The company plans to test mRNA-1273.351 and mRNA-1273.211 as major vaccine series for those who have not yet been vaccinated.
Increasing production
“We look forward to launching the clinical trial of boosting variants against the variants and we thank the National Institutes of Health for its continued cooperation in fighting this epidemic,” said Stefan Bensel, CEO of Moderna. To appoint the vaccine which are intended to provide a solution against the new variants of the virus. Modern is committed to updating vaccine versions as needed until we master the epidemic. We hope to show that boosting immunity, if needed, can also be done in smaller doses, which will allow us to provide much more doses to the global community in late 2021 and 2022 if need be. “
Modern announces additional investments in favor of increasing the global production capacity of the COVID-19 vaccine
Increased production capacity expected to 1.4 billion vaccine doses at a dose of 100 μg.
The new investments will enable additional production capability of Moderna’s current vaccine for COVID-19 and will allow for production flexibility should higher immunizations against the variants be required.
The original plan for 2021 has grown to produce 700 million vaccine doses and the company is working to provide up to 1 billion vaccine doses by 2021.
Up to 15 servings per vial
Moderna has received positive feedback from the FDA for its proposal to add additional vaccine doses to each vaccine vial, and the company is working on a plan that will allow the use of up to 15 vaccine doses per vial. Modern will work with additional regulatory agencies if required.
“We are investing in increasing production capacity to help us increase production and allow us flexibility in the production of potential booster vaccines, in order to address the new variants of the virus,” said Stefan Bensel, CEO of Moderna. 1.4 billion vaccine doses in 2022 at a discount and each dose will contain 100 μg. If the variants of booster vaccines require a smaller dose, for example 50 μg, we could produce more than 2 billion vaccine doses by 2022. “
More on the subject on the Yadan website: